Methods:
Despite a normal liver biopsy in November 2023 during her third
flare-up, she experienced severe hepatitis and was started on Rituximab,
which was discontinued six months later due to anaphylaxis after the
second dose. Currently, patient is experiencing high-grade fevers,
diffuse salmon-coloured rash, icteric sclera, brown urine, and grey
stools, complicating Still’s Disease, refractory to previous therapies.
Labs indicate elevated liver enzymes, indicative of acute severe
hepatitis. Figure 2 depicts the patient’s latest labs, upon her
4th flare up.